ETNB Novinky na Forexu

Biopharmaceutical company 89bio, Inc. (ETNB) announced Monday positive topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis (NASH).